Massive Nasal Bleeding in Patients With NPC Received Curative RT

Completed

• Conditions: Nasopharyngeal Carcinoma Patients Treated With Curative Radiotherapy

• Registration Number: NCT06348485
• Lead Sponsor: Taichung Veterans General Hospital

Brief Summary

To investigate the incidence, predictive markers, and survival impact of massive nasal bleeding in nasopharyngeal carcinoma (NPC) patients who received curative radiotherapy (RT) with/without chemotherapy. A total of 1327 patients with previously untreated, biopsy-proven NPC, and no distant metastasis were retrospective reviewed. Investigators analyzed the occurrence rates of massive nasal bleeding between different characteristics and tried to identify important predictive factors. Investigators compared overall survival between patients with and without massive nasal bleeding by Kaplan-Meier method.

Detailed Description

Not available

Study Timeline

• Study Start: 1994-12-01
• Primary Completion: 2019-04-30
• Study Completion: 2024-02-29
• Status Verified: 2024-03
• Study First Submitted: 2024-03-21
• Study First Submitted QC: 2024-03-31
• Last Update Submitted: 2024-03-31
• Study First Posted: 2024-04-04
• Last Update Posted: 2024-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1327

Inclusion Criteria

• previously untreated, biopsy-proven NPC
• no distant metastasis

Exclusion Criteria

• incomplete record of history or treatment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Massive Nasal Bleeding Rate	From date of radiotherapy until the date of first documented massive bleeding, assessed up to 360 months	Massive Nasal Bleeding Rate among different characteristics. Massive Nasal Bleeding was defined as unique blood loss \> 300 ml or recurrent blood losses \> 100 ml.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	From date of radiotherapy until the date of last clinic visit or date of death from any cause, whichever came first, assessed up to 360 months	Overall Survival

Trial Locations

Locations (1)

Taichung Veterans General Hospital; 🇨🇳 Taichung, Taiwan